Cure My Disease

Don't miss your cure!

 Log in / Sign up

A sticky patch could reveal hidden heart rhythm dangers

NCT ID NCT07792772

Disease control Sponsor: HUINNO Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether a wearable ECG patch called MEMO Patch Plus can detect clinically significant arrhythmias in adults hospitalized with acute heart failure. Participants wear the patch for up to 14 days in the hospital and again for up to 14 days after discharge. The study tracks how often the patch finds dangerous rhythms, such as atrial fibrillation or ventricular tachycardia, and whether that changes patient care. The goal is to see if extended monitoring can uncover heart rhythm problems that standard checks might miss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MEMO Patch Plus, a wearable, noninvasive electrocardiographic monitoring device
What this could lead to
If it works, this wearable patch could help doctors spot dangerous heart rhythms earlier in people with acute heart failure, potentially guiding treatment and preventing complications.
What could go wrong
This is a small, early exploratory study with only 45 participants, so results may not apply broadly. The patch may miss some arrhythmias or be uncomfortable, and detecting a rhythm does not guarantee improved outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Jul 2023

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participant aged 19 years or older * Participant who voluntarily agrees to participate in the clinical trial and provides written informed consent * Participant who is hospitalized for acute heart failure Acute heart failure is defined as worsening signs or symptoms of heart failure requiring an unplanned hospital admission or emergency department visit. Exclusion Criteria: * Participant who is unable to make a voluntary decision regarding participation in the clinical trial * Participant who is currently admitted to an intensive care unit * Participant diagnosed with any of the following clinically significant arrhythmias on the initial standard 12-lead electrocardiogram obtained after presentation: * A pause lasting 3 seconds or longer * High-degree atrioventricular block or complete atrioventricular block * Atrial fibrillation or atrial flutter * Supraventricular tachycardia, including atrial tachycardia and paroxysmal supraventricular tachycardia * Ventricular tachycardia * Ventricular fibrillation * Participant with a psychiatric disorder, including cognitive impairment or dementia, or a social circumstance that, in the investigator's judgment, may interfere with compliance with the clinical trial * Participant with a history of an allergic skin reaction to external medical electrodes or equivalent materials * Participant with a life expectancy of less than 3 months, as determined by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure (AHF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation atrial flutter heart failure ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure (AHF) Cardiac arrhythmia

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.